NDA Submission By Year End 2014 Says Needham (( posted ))
The Street Insider
Needham & Company analyst Alan Carr reiterated a Buy rating and boosted his priced target on Intercept Pharmaceuticals (NASDAQ: ICPT) from $320 to $500 following positive Phase 3 results for OCA in PBC.
Carr commented, "Intercept held a conference call to discuss 4Q13 financial results, outcome of Phase 3 OCA trial in PBC, and additional safety data from Phase 2 OCA trial in NASH (FLINT). Phase 3 PBC top-line results appear consistent with Phase 2 data and we expect an NDA submission by YE14
That is Good News BUT that is lots of time span to keep stock at this level. They better seek a partner with deep pockets to fund in the mean time. I hope these are not Greedy folks. May be GSK, GILD, Roche, SNY, MRK, PZE, AZN, AMGN, Novartis,....could make it happen.